UNITED STATES SECURITIES AND EXCHANGE COMMISSION February 5, 2009

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Interleukin Genetics, Inc. File No. 0-23413 CF# 22722

Interleukin Genetics, Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-QSB filed on November 15, 1999.

Based on representations by Interleukin Genetics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1	through November 15, 2011
Exhibit 10.2	through November 15, 2011
Exhibit 10.3	through November 15, 2011

For the Commission, by the Division of Corporation Finance, pursuant to the delegated authority:

Craig E. Slivka Special Counsel